Interesting update on the status of Campath
Genzyme bets Campath to be blockbuster
July 25, 2006 - Reuters - Genzyme is optimistic its cancer drug Campath will become a blockbuster if it is approved to treat multiple sclerosis, a senior executive said.
Campath, which is currently approved to treat B-cell chronic lymphocytic leukemia, a rare blood cancer, generated minimal sales in 2005.
But if the drug is approved for multiple sclerosis it could generate annual ...